Weighing the benefits of high-dose simvastatin against the risk of myopathy.

A. Egan,E. Colman
DOI: https://doi.org/10.1056/NEJMp1106689
IF: 158.5
2011-07-27
New England Journal of Medicine
Abstract:Having reviewed the data on the risk of myopathy, the FDA recommends that the 80-mg dose of simvastatin be used only in patients who have been taking this dose for an extended period without signs or symptoms of clinically significant muscle toxicity.
What problem does this paper attempt to address?